Christopher Peetz Sells 30,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at $18,622,574.56. This represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, March 16th, Christopher Peetz sold 40,985 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $91.98, for a total value of $3,769,800.30.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock opened at $92.03 on Thursday. The stock has a 50-day simple moving average of $97.13 and a 200 day simple moving average of $90.07. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 12-month low of $43.50 and a 12-month high of $114.99. The stock has a market capitalization of $5.61 billion, a price-to-earnings ratio of -6.76 and a beta of 0.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. During the same period in the prior year, the firm earned ($0.30) earnings per share. The business’s quarterly revenue was up 43.3% compared to the same quarter last year. On average, research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on MIRM. Citigroup began coverage on Mirum Pharmaceuticals in a report on Tuesday. They set a “buy” rating and a $145.00 price objective for the company. Stifel Nicolaus set a $136.00 price objective on Mirum Pharmaceuticals in a report on Thursday, May 7th. Leerink Partners dropped their price objective on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Royal Bank Of Canada boosted their price objective on Mirum Pharmaceuticals from $128.00 to $142.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Finally, Evercore reissued an “outperform” rating and set a $138.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $137.64.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC grew its position in shares of Mirum Pharmaceuticals by 14.5% during the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after buying an additional 880,505 shares during the period. Vanguard Group Inc. grew its position in shares of Mirum Pharmaceuticals by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock worth $205,065,000 after buying an additional 50,720 shares during the period. State Street Corp grew its position in shares of Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after buying an additional 797,088 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Mirum Pharmaceuticals by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock worth $112,196,000 after buying an additional 137,087 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of Mirum Pharmaceuticals by 56.6% during the 4th quarter. Wellington Management Group LLP now owns 1,237,830 shares of the company’s stock worth $97,776,000 after buying an additional 447,141 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.